TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23340449

Group type: EXPERIMENTAL
Intervention: DFMO+sulindac treatment in dietary polyamine quartiles 1-3
Number of subjects: 267

Group type: COMPARATOR
Intervention: Dietary polyamine quartile 4
Number of subjects: 267
Study: 21658349

Group type: EXPERIMENTAL
Intervention: 16 kcal per kg per week (KKW) exercise expenditure for 12 weeks
Number of subjects: 126

Group type: COMPARATOR
Intervention: 4 KKW exercise expenditure for 12 weeks
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 16 KKW exercise (women)
Number of subjects: 126

Group type: COMPARATOR
Intervention: 4 KKW exercise (women)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 16 KKW exercise (men)
Number of subjects: 126

Group type: COMPARATOR
Intervention: 4 KKW exercise (men)
Number of subjects: 126
Study: 19374892

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg single-oral dose) with rifampicin (600 mg single-oral dose)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Atorvastatin (40 mg single-oral dose) with placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rifampicin (450 mg single-oral dose)
Number of subjects: 16
Study: 17088091

Group type: EXPERIMENTAL
Intervention: Indacaterol 400 microg
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Indacaterol 800 microg
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Indacaterol (both doses)
Number of subjects: 163
Study: 16485735

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (CLS2210) given orally for 14 days before the operation (CD group)
Number of subjects: 24
Study: 14560084

Group type: EXPERIMENTAL
Intervention: Aspen orthosis
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Boston orthosis
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cybertech orthosis
Number of subjects: 12

Group type: COMPARATOR
Intervention: No orthosis
Number of subjects: 12
Study: 10720272

Group type: EXPERIMENTAL
Intervention: Embryonic porcine VM tissue with cyclosporine immunosuppression
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Embryonic porcine VM tissue treated with a monoclonal antibody directed against major histocompatibility complex class I
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study: 9016469

Group type: EXPERIMENTAL
Intervention: Resistive-load detection thresholds measured by forced oscillation
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tracking method
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Random method
Number of subjects: 38

Group type: COMPARATOR
Intervention: Comparison group of adults (n = 10)
Number of subjects: 38
Study: 1517950

Group type: EXPERIMENTAL
Intervention: Tryptophan-fortified formula
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tryptophan-unfortified formula
Number of subjects: 20

Group type: COMPARATOR
Intervention: Breast-fed
Number of subjects: 20
Study: 6829517

Group type: EXPERIMENTAL
Intervention: Paregoric
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 153

Group type: COMPARATOR
Intervention: No specific pharmacotherapy
Number of subjects: 153
Study: 29666180

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (ET)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 108
Study: 29183074

Group type: EXPERIMENTAL
Intervention: FMT by oral capsule
Number of subjects: 116
Study: 25316182

Group type: EXPERIMENTAL
Intervention: Conventional walking, endurance, balance, and strength (WEBS) intervention (n=20)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Timing and coordination of gait (TC) intervention (n=22)
Number of subjects: 44
Study: 23297781

Group type: EXPERIMENTAL
Intervention: Individual peer support
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Group peer support
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Combined peer support (individual and group)
Number of subjects: 165

Group type: COMPARATOR
Intervention: No peer support (control)
Number of subjects: 165
Study: 21719165

Group type: EXPERIMENTAL
Intervention: Standard glucose infusion (SG; 5.0 mg kg(‐1) min(‐1))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low glucose infusion (LG; 2.5 mg kg(‐1) min(‐1))
Number of subjects: 8
Study: 18329563

Group type: EXPERIMENTAL
Intervention: Propranolol (30 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 16401810

Group type: EXPERIMENTAL
Intervention: Emtricitabine 200 mg once daily for 48 weeks
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 15536785

Group type: EXPERIMENTAL
Intervention: Locally delivered minocycline microspheres (Arestin) as an adjunct to scaling and root planing (SRP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 20
Study: 11428837

Group type: EXPERIMENTAL
Intervention: Bisoprolol therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9284986

Group type: EXPERIMENTAL
Intervention: Inhalation of low doses of allergen
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (inhalation of PHA alone)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Both groups (allergen and placebo)
Number of subjects: 9
Study: 8328415

Group type: EXPERIMENTAL
Intervention: Group 1 (surface cooling)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Group 2 (surface warming and insulation)
Number of subjects: 29
Study: 3521401

Group type: EXPERIMENTAL
Intervention: Ethaverine 200 mg four times daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 31096265

Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg twice daily
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 29686481

Group type: EXPERIMENTAL
Intervention: Cervical manipulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 30
Study: 27183112

Group type: EXPERIMENTAL
Intervention: Laparoscopic complete mesocolic excision (CME)
Number of subjects: 0

Group type: COMPARATOR
Intervention: D3 lymphadenectomy
Number of subjects: 0
Study: 24183827

Group type: EXPERIMENTAL
Intervention: Simulator training
Number of subjects: 46

Group type: COMPARATOR
Intervention: Live volunteer training
Number of subjects: 46
Study: 23760155

Group type: EXPERIMENTAL
Intervention: Systemic inflammatory response syndrome at presentation
Number of subjects: 1903

Group type: EXPERIMENTAL
Intervention: Systemic inflammatory response syndrome at 24 hours
Number of subjects: 1903

Group type: EXPERIMENTAL
Intervention: Each additional systemic inflammatory response syndrome criterion at presentation
Number of subjects: 1903

Group type: EXPERIMENTAL
Intervention: Each additional systemic inflammatory response syndrome criterion at 24 hours
Number of subjects: 1903

Group type: EXPERIMENTAL
Intervention: Mortality at 90 days
Number of subjects: 1903
Study: 20568386

Group type: EXPERIMENTAL
Intervention: Ecallantide (30 mg subcutaneous)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 17534380

Group type: EXPERIMENTAL
Intervention: 0.1 mg nicotine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.4 mg nicotine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.7 mg nicotine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.4 mg and 0.7 mg nicotine
Number of subjects: 10
Study: 16912129

Group type: EXPERIMENTAL
Intervention: Hormone therapy (5 microg ethinyl estradiol and 1 mg norethindrone acetate)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12654170

Group type: EXPERIMENTAL
Intervention: 6.6 g n‐3 PUFA/d
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2.0 g n‐3 PUFA/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 60
Study: 10799791

Group type: EXPERIMENTAL
Intervention: Symptom severity
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Prior physical functioning
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Patient age
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Current symptomatology
Number of subjects: 129
Study: 8797007

Group type: EXPERIMENTAL
Intervention: Method to distinguish between susceptibility locus and necessary locus using linkage analysis and marker loci.
Number of subjects: 0
Study: 1495569

Group type: EXPERIMENTAL
Intervention: Fish oil (1800 mg EPA and 1200 mg DHA)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Corn oil (3000 mg omega-6 linoleic acid)
Number of subjects: 17
Study: 6089305

Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine twice daily
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 200 mg cimetidine three times daily and 400 mg at night
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo matching ranitidine twice daily
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine at night
Number of subjects: 58

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 58
Study: 30334082

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3234

Group type: EXPERIMENTAL
Intervention: Lifestyle
Number of subjects: 3234

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3234
Study: 30022618

Group type: EXPERIMENTAL
Intervention: Baerveldt glaucoma drainage device (BGI)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Trabeculectomy (TE)
Number of subjects: 119
Study: 27098500

Group type: EXPERIMENTAL
Intervention: Single-knot technique (SKT)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Multiple-knot technique (MKT)
Number of subjects: 260
Study: 24884787

Group type: EXPERIMENTAL
Intervention: Sitagliptin treatment (n=16)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional treatment (Control, n=10)
Number of subjects: 26
Study: 22261813

Group type: EXPERIMENTAL
Intervention: Active robot‐assisted intervention (FTI group, 20 sessions over 4 weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Early passive therapy followed by active robot‐assisted intervention (HTI group, 10 sessions of passive therapy followed by 10 sessions of active therapy)
Number of subjects: 17
Study: 19748619

Group type: EXPERIMENTAL
Intervention: EPA-rich oil (ERO, 3.3g EPA/day)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: DHA-rich oil (DRO, 3.7g DHA/day)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: DHA-rich oil (DRO)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control oil
Number of subjects: 38
Study: 17178187

Group type: EXPERIMENTAL
Intervention: Lidocaine 1%
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 32
Study: 15929759

Group type: EXPERIMENTAL
Intervention: Prototype pediatric colonoscope with short bending in four directions (PCF-AYL)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard pediatric colonoscope (Olympus PCF‐160)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Prototype pediatric colonoscope with short bending in two directions (PCF-AY3L)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Prototype 170 degrees wide angle colonoscope with standard bending section length (CFQ160-WL)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Prototype 170 degrees colonoscope with a short bending section (CFQ160-W2L)
Number of subjects: 174
Study: 12766103

Group type: EXPERIMENTAL
Intervention: Insulin glargine administered before breakfast
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Insulin glargine administered before dinner
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Insulin glargine administered at bedtime
Number of subjects: 378
Study: 10851101

Group type: EXPERIMENTAL
Intervention: Exercise therapy (4-week program focusing on strength and endurance of back and abdominal muscles)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (normal postoperative care with physiotherapist advice)
Number of subjects: 20
Study: 8671131

Group type: EXPERIMENTAL
Intervention: Electromagnetic therapy at 800 Hz
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo therapy or treatment with 600 Hz
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Electromagnetic therapy
Number of subjects: 19
Study: 1582116

Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Indomethacin (100 mg)
Number of subjects: 261
Study: 3907792

Group type: EXPERIMENTAL
Intervention: 3 micrograms/kg fentanyl followed by thiopentone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Thiopentone alone
Number of subjects: 28
Study: 29745007

Group type: EXPERIMENTAL
Intervention: ASP0113 (5 mg, 5 doses on Days 30/60/90/120/180 posttransplant)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: ASP0113
Number of subjects: 149
Study: 27349747

Group type: EXPERIMENTAL
Intervention: Palbociclib + Letrozole
Number of subjects: 165

Group type: COMPARATOR
Intervention: Letrozole alone
Number of subjects: 165
Study: 24718775

Group type: EXPERIMENTAL
Intervention: 3 mg oral melatonin
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 23302558

Group type: EXPERIMENTAL
Intervention: Clostridium butyricum and Bifidobacterium combined Powder (5×10^9 CFU daily for 7 days)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Control group (routine antibiotics treatment)
Number of subjects: 372
Study: 20395115

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 17644419

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for insomnia (three-component treatment: relaxation training, stimulus control, sleep hygiene instructions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 0
Study: 16010198

Group type: EXPERIMENTAL
Intervention: Tactile sensory threshold greater than 0.5 g
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Discriminability less than 0.50
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Forced-choice scores less than 90%
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Below-chance scores
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Scores beyond cut-offs
Number of subjects: 80
Study: 14714120

Group type: EXPERIMENTAL
Intervention: 20 mg fluoxetine daily
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 40 mg fluoxetine daily
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 20 mg fluoxetine once every third day
Number of subjects: 95
Study: 12172973

Group type: EXPERIMENTAL
Intervention: Heptaplatin 400 mg/m(2) i.v. over 1 h on day 1 plus 5‐fluorouracil (5‐FU) 1000 mg/m(2) per day continuous i.v. from day 1 to day 5
Number of subjects: 99

Group type: COMPARATOR
Intervention: Cisplatin 60 mg/m(2) i.v. over 1 h on day 1 plus 5‐fluorouracil (5‐FU) 1000 mg/m(2) per day continuous i.v. from day 1 to day 5
Number of subjects: 99
Study: 9708751

Group type: EXPERIMENTAL
Intervention: Standard therapy plus acetazolamide (100 mg/kg daily) and furosemide (1 mg/kg daily)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Standard therapy plus acetazolamide and furosemide
Number of subjects: 177
Study: 7608727

Group type: EXPERIMENTAL
Intervention: Condition A (baseline thermode temperature at 30 degrees C)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Condition B (baseline thermode temperature at 35 degrees C)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Condition C (baseline thermode temperature at 35 degrees C and warmed skin area to 35 degrees C)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Difference limen (DL) thresholds
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: General recommendation
Number of subjects: 20
Study: 2196030

Group type: EXPERIMENTAL
Intervention: Curosurf (200 mg/kg) given intratracheally
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no Curosurf)
Number of subjects: 30
Study: 117496

Group type: EXPERIMENTAL
Intervention: Incentive Gain Condition
Number of subjects: 40

Group type: COMPARATOR
Intervention: Incentive Loss Condition
Number of subjects: 40
Study: 6315123

Group type: EXPERIMENTAL
Intervention: Oral progesterone 100 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral progesterone 200 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral progesterone 300 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conjugated oestrogens 1.25 mg daily
Number of subjects: 0
Study: 30558672

Group type: EXPERIMENTAL
Intervention: Subcutaneous spacer injection (4-10 cc of biodegradable hyaluronic acid)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group (no spacer injection)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Subcutaneous spacer injection
Number of subjects: 230
Study: 26940095

Group type: COMPARATOR
Intervention: GSTM1 active/APOL1 low‐risk (reference group)
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: GSTM1 active/APOL1 high‐risk
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: GSTM1 null/APOL1 low‐risk
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: GSTM1 null/APOL1 high‐risk
Number of subjects: 682
Study: 25161019

Group type: COMPARATOR
Intervention: Standard polyurethane (SPU) dressing (control)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Bordered polyurethane (BPU) + SPU dressing
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Tissue adhesive (TA) + SPU dressing
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Sutureless securement device (SSD) + SPU dressing
Number of subjects: 195

Group type: COMPARATOR
Intervention: All groups compared to control (SPU)
Number of subjects: 195
Study: 22123332

Group type: EXPERIMENTAL
Intervention: Exposure with additional excitatory stimuli
Number of subjects: 59

Group type: COMPARATOR
Intervention: Exposure without additional excitatory stimuli
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Sustained arousal throughout exposure
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Variability in subjective fear responding during exposure
Number of subjects: 59
Study: 19513794

Group type: EXPERIMENTAL
Intervention: Local heating (Group 1)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Local cold stress (Group 2)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (t=0)
Number of subjects: 22
Study: 18762495

Group type: EXPERIMENTAL
Intervention: Behavior-modification program designed to improve infant sleep (n = 174) delivered by well-child nurses at ages 8 to 10 months
Number of subjects: 328

Group type: COMPARATOR
Intervention: Usual well-child care (n = 154)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Behavior-modification program designed to improve infant sleep (n = 174)
Number of subjects: 328
Study: 15975302

Group type: EXPERIMENTAL
Intervention: Yangxue Qingnao granule (YXQNG)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Nimodipine (ND)
Number of subjects: 83
Study: 12952839

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg per day
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg per day
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study: 10023697

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) at 500 mg/body/day for 7 days
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) at 500 mg/body/day for 3 days
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) at 500 mg/body/day for 5 days
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) at 500 mg/body/day for 10 days
Number of subjects: 41
Study: 8683517

Group type: EXPERIMENTAL
Intervention: Hackett's AMS score
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Lake Louise AMS score
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Oxygen saturation
Number of subjects: 99
Study: 1496150

Group type: EXPERIMENTAL
Intervention: Preadmission self-instruction
Number of subjects: 50

Group type: COMPARATOR
Intervention: Posthospital admission instruction of therapeutic exercises
Number of subjects: 50
Study: 6541929

Group type: EXPERIMENTAL
Intervention: 20 mg oxazolam with 0.55 g/kg alcohol
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 60 mg oxazolam with 0.55 g/kg alcohol
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 20 mg oxazolam with 0.83 g/kg alcohol
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo with 0.55 g/kg alcohol
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo with 0.83 g/kg alcohol
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 30835629

Group type: EXPERIMENTAL
Intervention: FertiQOL score
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Depression (PHQ-9 score of 5 or greater)
Number of subjects: 708

Group type: COMPARATOR
Intervention: Low total testosterone
Number of subjects: 708

Group type: COMPARATOR
Intervention: Erectile dysfunction
Number of subjects: 708
Study: 30126766

Group type: EXPERIMENTAL
Intervention: Partner in Sight (ESM self-monitoring and personalized feedback)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Pseudo-intervention (ESM self-monitoring without feedback)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 76
Study: 27449412

Group type: EXPERIMENTAL
Intervention: GCSB-5 600 mg, bid for 12 weeks
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo, bid for 12 weeks
Number of subjects: 220
Study: 25299668

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (1,200 mg) and cholecalciferol [2,000-6,000 IU] for 6 months
Number of subjects: 95

Group type: COMPARATOR
Intervention: Matching placebos for 6 months
Number of subjects: 95
Study: 22482863

Group type: EXPERIMENTAL
Intervention: LI-guided pre-emptive therapy (group 3, n = 71)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Conventional treatment (group 2, n = 142)
Number of subjects: 560
Study: 20360754

Group type: EXPERIMENTAL
Intervention: Mild cold exposure (16 degrees C) for 48 hours after 36 hours at neutral temperature (22 degrees C)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mild cold exposure (16 degrees C) for 48 hours
Number of subjects: 20
Study: 18294477

Group type: EXPERIMENTAL
Intervention: Standard therapy plus pacemaker implantation and β-blocker therapy
Number of subjects: 1124

Group type: COMPARATOR
Intervention: Standard therapy (no β-blockers)
Number of subjects: 1124
Study: 15949431

Group type: EXPERIMENTAL
Intervention: RFA plus PEI (group B)
Number of subjects: 150

Group type: COMPARATOR
Intervention: RFA alone (group A)
Number of subjects: 150